Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-Current Debt (2017 - 2025)

Ani Pharmaceuticals' Non-Current Debt history spans 9 years, with the latest figure at $291.8 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 5.59% year-over-year to $291.8 million; the TTM value through Dec 2025 reached $291.8 million, down 5.59%, while the annual FY2025 figure was $291.8 million, 5.59% down from the prior year.
  • Non-Current Debt for Q4 2025 was $291.8 million at Ani Pharmaceuticals, down from $297.7 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $312.9 million in Q3 2024 and bottomed at $169.0 million in Q1 2021.
  • The 5-year median for Non-Current Debt is $285.8 million (2022), against an average of $275.1 million.
  • The largest annual shift saw Non-Current Debt dropped 10.16% in 2021 before it skyrocketed 69.43% in 2022.
  • A 5-year view of Non-Current Debt shows it stood at $286.5 million in 2021, then dropped by 0.3% to $285.7 million in 2022, then dropped by 0.3% to $284.8 million in 2023, then rose by 8.53% to $309.1 million in 2024, then decreased by 5.59% to $291.8 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Non-Current Debt are $291.8 million (Q4 2025), $297.7 million (Q3 2025), and $301.5 million (Q2 2025).